3-aminobenzamide and quinoxalines

3-aminobenzamide has been researched along with quinoxalines in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hattori, K; Ishida, J; Iwashita, A; Matsuoka, N; Matsuura, S; Mihara, K; Mutoh, S; Yamamoto, H; Yamazaki, S	1

Other Studies

1 other study(ies) available for 3-aminobenzamide and quinoxalines

Article	Year
A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 310, Issue:3 Topics: Animals; Benzamides; Body Temperature; Brain; Corpus Striatum; Dopamine; Enzyme Inhibitors; Lipid Peroxidation; Methamphetamine; Mice; Mice, Inbred C57BL; Neuroprotective Agents; PC12 Cells; Poly(ADP-ribose) Polymerase Inhibitors; Quinoxalines; Rats; Substantia Nigra	2004

Article

Year

A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice.

The Journal of pharmacology and experimental therapeutics, 2004, Volume: 310, Issue:3

Topics: Animals; Benzamides; Body Temperature; Brain; Corpus Striatum; Dopamine; Enzyme Inhibitors; Lipid Peroxidation; Methamphetamine; Mice; Mice, Inbred C57BL; Neuroprotective Agents; PC12 Cells; Poly(ADP-ribose) Polymerase Inhibitors; Quinoxalines; Rats; Substantia Nigra

2004